Key Takeaways
- Health experts outraged over CDC's plan to fund vaccine trial in Guinea-Bissau.
- Trial would expose newborns to hepatitis B, risking lifelong infection and severe health issues.
- Funding of $1.6 million from CDC's global health security programs proposed.
Health experts are expressing strong opposition to a reported plan by the Centers for Disease Control and Prevention (CDC) to fund a controversial vaccine trial in Guinea-Bissau. The trial, which was suspended in January due to its unethical design, would expose newborns to hepatitis B, a virus that can lead to lifelong infections, liver cirrhosis, liver cancer, and premature death.
According to a report by Rolling Stone, CDC staff instructed the agency's budget office in late September to allocate $1.6 million from the CDC's global health security programs to fund the trial. This funding would come at the expense of other critical health initiatives, such as combating the ongoing Ebola outbreak in the Democratic Republic of the Congo.
The trial, which was halted in January, had already faced significant backlash from the international community. Despite the suspension, the CDC's apparent willingness to fund the trial has reignited concerns about the ethical standards of the agency and its commitment to public health.
When contacted by Ars Technica, the Department of Health and Human Services, which oversees the CDC, did not respond to a request for comment. The lack of official response has further fueled the controversy surrounding the proposed funding.
The trial in question was designed to test a vaccine that could potentially prevent hepatitis B in newborns. However, the ethical concerns stem from the fact that the trial was halted due to its high risk to the participants, who are among the most vulnerable members of the population.
Health professionals argue that funding such a trial, which poses significant risks to newborns, is not only unethical but also a misallocation of resources that could be better spent on more effective and safer public health interventions.
The proposed funding has sparked a debate within the scientific community about the priorities of the CDC and the ethical considerations in vaccine trials. Critics are calling for a thorough review of the agency's decision-making process and a commitment to transparency and ethical standards in all future research initiatives.
